BOSTON SCIENTIFIC CORP

Cross-vertical regulatory timeline · last 365 days · 100 events

BOSTON SCIENTIFIC CORP is tracked across 5 federal verticals with 119 regulatory events in the last 365 days. Every event below traces to a primary US-government source listed in the References section.

Identifiers

Activity breakdown

Timeline

  1. sec.insider.i Monson Jonathan EVP and CFO $500.0K
  2. FDA recall Boston Scientific Corporation Class II
    There is potential for a delay in AF Burden Alert notification affecting the server software which supports the Insertable Cardiac Monitors (ICMs). Delayed notification of an AF Burden Alert may delay clinical evaluation or therapeutic inte
  3. FDA recall Boston Scientific Corporation Class II
    There is potential for a delay in AF Burden Alert notification affecting the server software which supports the Insertable Cardiac Monitors (ICMs). Delayed notification of an AF Burden Alert may delay clinical evaluation or therapeutic inte
  4. FDA recall Boston Scientific Corporation Class II
    There is potential for a delay in AF Burden Alert notification affecting the server software which supports the Insertable Cardiac Monitors (ICMs). Delayed notification of an AF Burden Alert may delay clinical evaluation or therapeutic inte
  5. FDA recall Boston Scientific Corporation Class II
    Device may fail to deploy the cinch implant and/or fail to cut the suture as intended.
  6. FDA recall Boston Scientific Corporation Class II
    Device may fail to deploy the cinch implant and/or fail to cut the suture as intended.
  7. FDA recall Boston Scientific Corporation Class I
    Potential for arterial sheath tip separation or partial tip separation during use.
  8. FDA recall Boston Scientific Corporation Class I
    Potential for arterial sheath tip separation or partial tip separation during use.
  9. sec.insider.f Monson Jonathan EVP and CFO $43.5K
  10. Option exercise Monson Jonathan EVP and CFO
  11. FDA recall Boston Scientific Corporation Class II
    Devices contain recalled Medline Namic Angiographic Control Syringe with Rotating Adaptor. There is a risk of syringe loosening or disconnecting from the manifold, resulting in loose connection or complete disconnection. May lead to difficu
  12. SEC filing 11-K — BOSTON SCIENTIFIC CORP — 2026-06-24
  13. FDA recall Boston Scientific Corporation Class II
    Software anomaly occurs when a user adds one or more vials to the cart and subsequently returns to the Activity Calculator to modify one or more input. When a user modifies an input and selects "Recalculate", the dose calculation is update
  14. FDA recall Boston Scientific Corporation Class II
    Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in
  15. FDA recall Boston Scientific Corporation Class II
    Boston Scientific is replacing specific FARASTAR PFA generators which have a configuration that is not compatible for use with the FARAPOINT PFA catheter.
  16. FDA recall Boston Scientific Corporation Class II
    Labeling discrepancy: Devices distributed with Instructions For Use (IFU) did not include FARAPOINT PFA catheter information.
  17. FDA recall Boston Scientific Corporation Class II
    Labeling discrepancy: Devices distributed with Instructions For Use (IFU) did not include FARAPOINT PFA catheter information.
  18. FDA recall Boston Scientific Corporation Class II
    Labeling discrepancy: Devices distributed with Instructions For Use (IFU) did not include FARAPOINT PFA catheter information.
  19. FDA recall Boston Scientific Corporation Class II
    Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in
  20. FDA recall Boston Scientific Corporation Class II
    Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in
  21. FDA recall Boston Scientific Corporation Class II
    Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in
  22. sec.insider.g Mahoney Michael F Chairman, President & CEO
  23. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  24. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  25. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  26. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  27. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  28. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  29. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  30. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  31. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  32. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  33. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  34. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  35. SEC filing 4 — Habiger David C — 2026-05-21
  36. SEC filing SD — BOSTON SCIENTIFIC CORP — 2026-05-21
  37. Insider buy LUDWIG EDWARD J Common Stock $202.9K
  38. Insider buy Habiger David C Common Stock $125.8K
  39. Insider buy Pegus Cheryl Common Stock $100.0K
  40. Insider buy Habiger David C Common Stock $125.3K
  41. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-05-18
  42. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-05-18
  43. Clinical trial Boston Scientific Corporation Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
    ["Chronic Low-back Pain","Vertebrogenic Pain Syndrome"]
  44. Clinical trial Boston Scientific Corporation SIMPLAAFY Clinical Trial
    ["Atrial Fibrillation","Stroke","Bleeding"]
  45. Clinical trial Boston Scientific Corporation Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)
    ["Orthostatic Hypotension","Reflex Syncope"]
  46. Clinical trial Boston Scientific Corporation cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
    ["Concomitant Procedures","Atrial Fibrillation","PFA","LAAC"]
  47. Clinical trial Boston Scientific Corporation A DirEct to PatieNt Study in Chronic Pain
    ["Chronic Pain"]
  48. FDA recall Boston Scientific Corporation Class II
    Boston Scientific is initiating a medical device removal of Orca Sterile, Single Use Air/Water and Suction Valves due to a higher than anticipated occurrence of the suction button sticking.
  49. Clinical trial Boston Scientific Corporation IT Matters: The Erectile Restoration Registry
    ["Erectile Dysfunction"]
  50. Clinical trial Boston Scientific Corporation Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
    ["Prostate Cancer"]
  51. FDA recall Boston Scientific Corporation Class II
    There is the potential for leakage along the drug pathway from the pump through the end of the catheter.
  52. Clinical trial Boston Scientific Corporation Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)
    ["Coronary Artery Disease"]
  53. Clinical trial Boston Scientific Corporation OPTION-EMEA Clinical Trial
    ["Atrial Fibrillation (AF)","Stroke Prevention in Patients With Atrial Fibrillation","Left Atrial Appendage Closure","Pulsed Field Ablation","Atrial Fibrillation Ablation Procedure","Concomitant Procedures"]
  54. Clinical trial Boston Scientific Corporation A Prospective, Multi-center Study to Evaluate Efficacy and Safety of BSJ020R in Treatment of AVF for Hemodialysis (RANGER AV Japan Study)
    ["Arteriovenous Fistula Stenosis","Arteriovenous Fistula","Vascular Access"]
  55. Clinical trial Boston Scientific Corporation Paresthesia-Free Fast-Acting Subperception (FAST) Study
    ["Chronic Pain"]
  56. Clinical trial Boston Scientific Corporation Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
    ["Essential Tremor"]
  57. Clinical trial Boston Scientific Corporation AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
    ["Coronary Arterial Disease (CAD)","de Novo Lesions in Native Coronary Arteries"]
  58. Clinical trial Boston Scientific Corporation Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area
    ["Anastomotic Leaks","Hartmanns Stump Leakage"]
  59. Insider grant LUDWIG EDWARD J Common Stock
  60. Insider grant Habiger David C Common Stock
  61. Insider grant Zane Ellen M Common Stock
  62. Insider grant WICHMANN DAVID S Common Stock
  63. Clinical trial Boston Scientific Corporation AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE
    Sponsor Decision
  64. Clinical trial Boston Scientific Corporation Patient Retrospective Outcomes (PRO)
    ["Chronic Pain"]
  65. Clinical trial Boston Scientific Corporation Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System
    ["Paroxysmal Atrial Fibrillation","Persistent Atrial Fibrillation"]
  66. Clinical trial Boston Scientific Corporation A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure
    ["Atrial Arrhythmia","Intracardiac Echocardiography"]
  67. Clinical trial Boston Scientific Corporation Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
    ["Heart Failure - NYHA II - IV"]
  68. Clinical trial Boston Scientific Corporation A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
    ["Atrial Fibrillation (AF)","Persistant Atrial Fibrillation"]
  69. Clinical trial Boston Scientific Corporation Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
    ["Persistent Atrial Fibrillation"]
  70. Clinical trial Boston Scientific Corporation Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
    ["Pulmonary Embolism"]
  71. Clinical trial Boston Scientific Corporation RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)
    ["Cardiac Arrythmias"]
  72. Clinical trial Boston Scientific Corporation Feasibility Study of the FARAFLEX Mapping and PFA System
    ["Atrial Fibrillation","Persistent Atrial Fibrillation","Paroxysmal AF"]
  73. Clinical trial Boston Scientific Corporation PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)
    ["Persistent Atrial Fibrillation"]
  74. Clinical trial Boston Scientific Corporation A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism
    ["Acute Pulmonary Embolism"]
  75. Clinical trial Boston Scientific Corporation TheraSphere With Durvalumab and Tremelimumab for HCC
    ["Hepatocellular Carcinoma"]
  76. Clinical trial Boston Scientific Corporation A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
    ["Glioblastoma Multiforme","Recurrent Glioblastoma"]
  77. Clinical trial Boston Scientific Corporation Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
    ["Prostate","Cancer"]
  78. Clinical trial Boston Scientific Corporation BoStOn SCientific Rhythm MAnagemenT REgiStry (SOCRATES)
    ["Cardiac Disease"]
  79. Clinical trial Boston Scientific Corporation Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
    ["Heart Failure","Congestive Heart Failure"]
  80. Clinical trial Boston Scientific Corporation A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)
    ["In-Stent Restenosis"]

References

  1. SEC EDGAR filings for BOSTON SCIENTIFIC CORP · Retrieved 2026-09-16 · 17 events in window
  2. openFDA — recalls, drug labels, adverse events · Retrieved 2026-09-16 · 43 events in window
  3. ClinicalTrials.gov registry · Retrieved 2026-09-16 · 57 trials